Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting NCT06616961 Sponsor: Popular Medical College Hospital Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting

NCT06616961
Not Yet Recruiting Phase 3

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Consent to participate must be given before any trial-related activities begin
  • Adults aged 18 years or older at the time of signing the consent form, of any gender
  • People with a BMI of 30 or above, with or without weight-related health conditions, or a BMI between 25 and 29.9 with at least one weight-related health condition (such as high blood pressure, abnormal cholesterol levels, obstructive sleep apnea, or heart disease) that has been present for more than three months
  • For people with type 2 diabetes: a diagnosis of type 2 diabetes made at least 180 days before the screening visit
  • For people with type 2 diabetes: a blood sugar control measure (HbA1c) of up to 12.0%

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who report losing more than 5 kg of body weight in the 30 days before screening
  • People who have taken any medication specifically for obesity in the 90 days before screening (for example, Orlistat, liraglutide, naltrexone/bupropion, or similar medicines)
  • People who have previously had weight loss surgery or a weight loss device at any point in their life
  • People currently taking certain diabetes or blood sugar medications (GLP-1 agonists, SGLT-2 inhibitors, or metformin), unless a doctor decides these can be safely stopped, with a two-week break before joining (or a ten-week break if the medication is semaglutide/ORSEMA)
  • People currently taking oral or injectable steroids for any other health condition
  • People with a past history of pancreatitis (inflammation of the pancreas)
  • People diagnosed with an eating disorder such as bulimia nervosa
  • People with a previous history of suicide attempts, major depressive disorder (as defined by DSM-V criteria), schizophrenia, or obesity caused by antipsychotic medication
  • People with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or multiple endocrine neoplasia syndrome type 2 (a genetic hormonal condition)
  • People with a known allergic reaction to semaglutide or any of its ingredients
  • People who have had a heart attack in the past three months
  • People who are pregnant or breastfeeding
  • People with uncontrolled or newly identified thyroid disease, based on a thyroid hormone level (TSH) outside the range of 0.4–6.0 mIU/L at screening (people with well-controlled thyroid disease whose levels fall within this range may still be considered)
  • People with severely reduced kidney function, measured as an eGFR below 15 ml/min/1.73 m² (confirm with trial site)
  • For people without type 2 diabetes: a blood sugar control measure (HbA1c) of 6.5% (48 mmol/mol) or higher
  • For people with type 2 diabetes: severely reduced kidney function, defined as an eGFR below 30 mL/min/1.73 m² (or below 60 mL/min/1.73 m² for those taking an SGLT-2 inhibitor)
  • For people with type 2 diabetes: an HbA1c above 12.0%, indicating poorly controlled blood sugar that may require additional medications that could interfere with the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026

If you need support right now

This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.

If you or someone else is in immediate danger, call 000.

  • Lifeline — 24/7 crisis support: 13 11 14
  • Suicide Call Back Service — 24/7 counselling: 1300 659 467
  • 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
  • Beyond Blue — 24/7 mental health support: 1300 22 4636
  • Emergency: 000

Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.

Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.

Contact this trial

Phone: +8801767818973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Popular Medical College Hospital
Registry
ClinicalTrials.gov
Start date
1 November 2024
Est. completion
1 February 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

Bangladesh

Primary endpoints

Body Weight (kg)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov